Strengthening commercial and RampD in the US

>> YOUR LINK HERE: ___ http://youtube.com/watch?v=h13CttYwCMo

Novartis is transforming into a ‘pure-play’ Innovative Medicines company. • In a recent Meet Novartis Management Investor Relations session, Rod Wooten, Head of Global Product Strategy Capabilities at Novartis outlines how strengthening our commercial and R D interplays in the US is a critical component of our strategic focus and long-term performance. • • Our refreshed strategy and the role of the US in strengthening our commercial and R D approach is summarized in this short extract. • Meet Novartis Management • Event Date: September 22, 2022 • Investors Page: https://bit.ly/3HjdDWX • Link to Novartis Strategy: https://bit.ly/3iP8cpp • Disclaimer: Meet Novartis Management event contains forward-looking statements. Such forward-looking statements are subject to significant known and unknown risks and uncertainties. Visit our website for more information: https://bit.ly/3HiI7IO • Follow @Novartis on Twitter: / novartis • Follow Novartis on LinkedIn: / novartis

#############################

New on site